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To the Editor: Moyamoya disease presents most 
often as a transient ischemic attack or stroke. 
Apart from surgical revascularization procedures, 
medical therapeutic measures such as antiplate-
let agents and even anticoagulation have been 
used for stroke prevention. In completed stroke, 
as confirmed by means of diffusion-weighted 
magnetic resonance imaging, antiplatelet agents 
should be administered to reduce the formation 
of microthrombi at the site of the stenosis.
We would like to raise a question about throm-
bolytic therapy with the use of tissue plasmino-
gen activator (t-PA), which is today an accepted 
treatment for ischemic strokes. The threat of 
hemorrhage from the fragile collateral vessels 
that develop as compensation for carotid artery 
stenosis might prevent application of this effec-
tive therapy. Have there been any reports about 
stroke in patients with moyamoya disease who 
were treated with t-PA, perhaps in patients in 
whom the diagnosis of the underlying vasculop-
athy was revealed subsequently? Should moya-
moya disease be considered to be a contraindica-
tion for t-PA administration?
Lea Pollak, M.D.
Assaf Harofeh Medical Center 
70315 Zerifin, Israel 
lea.pollak@gmail.com
The Authors Reply: We appreciate the comments 
of both Derdeyn and Pollak regarding our review 
of moyamoya syndrome and moyamoya disease. 
Derdeyn points out that the natural history of 
North American adults with the “angiographic 
disorder” of moyamoya is unknown and that the 
typical North American adult with moyamoya is 
a woman in the fourth or fifth decade of life 
presenting with ischemic symptoms. In our small 
series of adult patients with moyamoya, ages 
ranged from 21 to 50 years at the time of their 
revascularization surgery and 19 of 20 patients 
were female. Twelve of these women presented 
with strokes (four of which were bilateral), and 
one presented with intracranial hemorrhage. We 
do not believe that our patients’ history of ischemic 
symptoms or strokes can be considered benign. 
In the article by Hallemeier et al. referenced in 
Derdeyn’s letter, the 5-year risk of recurrent 
stroke in the patients treated only medically was 
65%. These two series show that adult patients 
with moyamoya do not have a “benign clinical 
course,” and we believe that at the completion of 
Derdeyn’s NIH-funded natural-history study, his 
conclusions will probably be similar to ours.
In answer to Pollak’s query regarding the use 
of thrombolytic therapy for stroke in moyamoya 
disease and moyamoya syndrome: we did not en-
counter any reports of such treatment in prepar-
ing our review. Moreover, many strokes in moya-
moya appear to be caused by hemodynamic factors 
rather than by thrombus formation and emboliza-
tion. Since patients with moyamoya have a risk 
of hemorrhage in areas of extensive formation of 
moyamoya collateral vessels, we would be reluc-
tant to recommend thrombolytic therapy in a pa-
tient with moyamoya who has just had a stroke.
R. Michael Scott, M.D. 
Edward R. Smith, M.D.
Children’s Hospital Boston 
Boston, MA 02115 
edward.smith@childrens.harvard.edu
BRAF Mutation in Metastatic Colorectal Cancer
To the Editor: We recently found that progres-
sion-free survival was shorter among patients with 
metastatic colorectal cancer treated with chemo-
therapy, bevacizumab, and cetuximab (CBC regi-
men) than among patients who received chemo-
therapy and bevacizumab alone (CB regimen) 
(Feb. 5 issue).1 Other investigators have found 
that the efficacy of cetuximab is limited to pa-
tients with wild-type–KRAS tumors.2 In a subgroup 
of 520 patients with available tumor samples, we 
observed a shorter median progression-free sur-
vival among patients with a mutated-KRAS onco-
gene in the CBC group than among patients with 
mutated-KRAS tumors who received the CB regi-
men and among  patients with wild-type–KRAS 
tumors who received the CBC regimen. An activat-
ing mutation in the B-type Raf kinase (BRAF) onco-
gene encoding the BRAF protein, localized direct-
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ly downstream of RAS, leads to stimulation of 
the mitogen-activated protein kinase pathway.3 
In a recent study, the efficacy of antibody therapy 
against the epidermal growth factor receptor for 
wild-type–KRAS  tumors appeared to be restrict-
ed to wild-type–BRAF tumors.4 We performed a 
retrospective analysis of the BRAF V600E muta-
tion status in 519 tumors that were tested in our 
study to determine KRAS status. A BRAF muta-
tion was detected in 45 tumors (8.7%) (Table 1). 
BRAF and KRAS mutations were mutually exclu-
sive. Patients with BRAF-mutated tumors had a 
significantly shorter median progression-free 
and median overall survival than patients with 
wild-type–BRAF tumors, both in the CB group 
and in the CBC group (Table 1). No difference in 
response rate was observed. We conclude that a 
BRAF mutation is a negative prognostic marker 
in patients with metastatic colorectal cancer and 
that this effect, in contrast to KRAS mutations, 
is not restricted to the outcome of cetuximab 
treatment.
Jolien Tol, M.D. 
Iris D. Nagtegaal, M.D., Ph.D. 
Cornelis J.A. Punt, M.D., Ph.D.
Radboud University Nijmegen Medical Center 
6500HB Nijmegen, the Netherlands 
c.punt@onco.umcn.nl
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Table 1. Association of the Mutation Status of the BRAF Oncogene 
with Progression-free Survival, Overall Survival, and Response Rate.*
Variable
Wild-Type 
BRAF
Mutated 
BRAF P Value
No. of patients
CB group 243 17
CBC group 231 28
Median progression-free survival (mo)
CB group 12.2 5.9 0.003
CBC group 10.4 6.6 0.010
Median overall survival (mo)
CB group 24.6 15.0 0.002
CBC group 21.5 15.2 0.001
Response rate (%)
CB group 50 35 0.32
CBC group 48 39 0.43
* BRAF denotes B-type Raf kinase, CB capecitabine, oxaliplatin, and bevacizu-
mab, and CBC capecitabine, oxaliplatin, and bevacizumab plus cetuximab.
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